Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells

Last updated: January 8, 2024
Sponsor: IRCCS San Raffaele
Overall Status: Active - Recruiting

Phase

N/A

Condition

Renal Cell Carcinoma

Renal Cell Cancer

Kidney Cancer

Treatment

Blood and urine sample collection

Clinical Study ID

NCT06194669
SoMuKT
  • Ages > 18
  • All Genders

Study Summary

The goal of this observational study is to analyze somatic mutations in the genome of normal kidney cells from patients affected by kidney cancer predisposition syndrome Von Hippel Lindau (VHL) and compare the mutation rates observed in these patients and in individuals not affected by the disease. The main questions the study aims to answer are:

  • Do kidney cells from VHL patients mutate more than cells from control individuals during adult life?

  • What mechanisms favor somatic mutation occurrence in the genome of normal kidney tubule cells?

Participants will donate one blood sample and multiple urine samples. Urines will be used for kidney cell isolation, followed by cell culturing and genetic analyses. Urine samples will be collected once a year for 3-5 years. Sample collection will occur during the yearly screening program that each patient undergoes at the hospital. In case patients undergo surgical treatment of kidney tumors, samples discarded from surgery (tumor and normal kidney adjacent to tumor) will be collected and subjected to genetic analyses.

Researchers will compare the number and types of mutations found in tumors and normal kidney cells from VHL-disease patients with those found in normal kidney cells from control individuals, to see if somatic mutation rates are increased in VHL-disease patients during aging.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Genetic diagnosis of VHL-disease; age (data need to be collected from a populationdistributed between 25 and 65 years); gender (males and females should be equallyrepresented);

Exclusion

Exclusion Criteria:

  • patients with bilateral nephrectomy, in dialysis or kidney transplant; use ofnephrotoxic drugs

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Blood and urine sample collection
Phase:
Study Start date:
June 30, 2023
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • IRCCS Ospedale San Raffaele

    MIlan, 20132
    Italy

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.